HCPCS J9999: Not Otherwise Classified Antineoplastic Drug
Commercial payers pay $1899 on average nationally for this procedure.
HCPCS Level II code J9999 denotes a not otherwise classified antineoplastic drug used for chemotherapy or cancer-directed pharmacotherapy; service type: administration of an antineoplastic agent, typically provided in hospital outpatient infusion centers, physician office infusion suites, or oncology clinics as part of systemic cancer treatment.
For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only), Umbilical Cord Blood Harvesting and Storage for Future Use (for Indiana Only).
Customize your policy alerts
Sign up for hcpcs J9999 policy alerts
Get alerted when payer policies referencing J9999 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial rates for HCPCS J9999 vary substantially across carriers. BUCA’s average commercial rate sits at $1,899.50, serving as a broad-market reference; Blue Cross Blue Shield displays a tight distribution with an interquartile range (P75–P25) of $22.10, and UnitedHealth Group is similarly constrained with an IQR of $22.80. Cigna’s spread is narrower still at $21.00. In contrast, Aetna exhibits extreme dispersion driven by high outliers, with an IQR of $15,480.30, indicating a highly fragmented pricing environment for that payer.
When comparing dispersion, Aetna is the widest by far, reflecting large variability in allowed amounts. Blue Cross Blue Shield, UnitedHealth Group, and Cigna show the tightest quartile spreads and thus more consistent commercial pricing. BUCA’s provided percentiles place it between these groups, with a P25 of $13.00, a median of $23.60, and a P75 of $3,127.00, indicating moderate skew toward higher values above the median.